Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study

Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study

Abstract Background Chronic migraine (CM) is a disabling condition with high prevalence in the general population. Until the recent approval of monoclonal antibodies targeting the calcitonin gene-related peptide (Anti-CGRP mAbs), OnabotulinumtoxinA (BoNT-A) was the only treatment specifically approv...

Full description

Bibliographic Details
Main Authors: Licia Grazzi, Riccardo Giossi, Danilo Antonio Montisano, Mattia Canella, Marilena Marcosano, Claudia Altamura, Fabrizio Vernieri
Format: Article
Language:English
Published: BMC 2024-02-01
Series:The Journal of Headache and Pain
Subjects:
Migraine
Erenumab
Galcanezumab
Fremanezumab
Onabotulinumtoxin
Online Access:https://doi.org/10.1186/s10194-024-01721-6

Internet

https://doi.org/10.1186/s10194-024-01721-6

Similar Items